WO1983001738A1 - Intravascularly administrable, magnetically responsive nanosphere or manoparticle, a process for the production thereof, and the use thereof - Google Patents
Intravascularly administrable, magnetically responsive nanosphere or manoparticle, a process for the production thereof, and the use thereof Download PDFInfo
- Publication number
- WO1983001738A1 WO1983001738A1 PCT/SE1982/000381 SE8200381W WO8301738A1 WO 1983001738 A1 WO1983001738 A1 WO 1983001738A1 SE 8200381 W SE8200381 W SE 8200381W WO 8301738 A1 WO8301738 A1 WO 8301738A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanosphere
- nanopartiele
- carbohydrate
- matrix
- magnetic material
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0063—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use in a non-magnetic matrix, e.g. granular solids
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/701—Integrated with dissimilar structures on a common substrate
- Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component
- Y10S977/706—Carbohydrate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
- Y10S977/776—Ceramic powder or flake
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/832—Nanostructure having specified property, e.g. lattice-constant, thermal expansion coefficient
- Y10S977/838—Magnetic property of nanomaterial
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
Definitions
- the present invention relates to a magnetically responsive and biologically degradable nanosphere or nanopartiele for intravascular administration, to a process for the production thereof, and to the use thereof for the transport and concentration of pharma ⁇ ceuticals.
- mag- netic carriers of pharmaceuticals which are injected into the blood-vessel system and transported by the blood to be stopped at the target by means of a magnetic field.
- US-PS 4,335,094 discloses microspheres containing magnetic material incorporated with a polymer which, in addition, carries biologically active components.
- US-PS 4,247,406 contains a detailed description of the use and production of magnetic microspheres made up of a magnetic material which has been enclosed in a polymer consisting of albumin.
- mag ⁇ netic material in a matrix, and for not using only the magnetic material, is that a matrix makes it possible to transport greater amounts of pharmalogically active substance per icrosphere or microparticle, which is a prior condition of opening up possibilities of pro- viding therapeutical concentrations of the pharmacolo ⁇ gically active substances at the target site, without increasing the number of microspheres to such an extent that the capillaries are occluded.
- the requirements placed on the matrix used in such contexts are as fol- lows:
- the matrix should in itself be chemically inert in biological systems.
- the matrix should be biologically well-characterised.
- the matrix should be non-toxic and non-immunogenic. 4. The matrix should be dischargeable from the body via normal routes.
- the matrix preparation should be readily administrable.
- the matrix preparation should be able to release a biologically active substance, and the release rate of the active substance should be readily con ⁇ trollable.
- the matrix should be usable for enclosing and re ⁇ leasing substances having different molecular weights.
- starch and gly- cogen are such carbohydrates made up of glucose units and satisfying the requirements for biocompatibility, primarily because they are the body's own substances, which means that secondary effects in the form of hyper- sensitivity reactions are avoided.
- the body's own enzyme for degrading starch is alpha-amylase which specifically degrades alpha(1-4) bonds.
- starch is disclosed by DE-OS 25 24 278 which describes the preparation and utilization of co- valent cross-linked microspheres of starch having a size so selected that the microspheres will get caught in the capillaries and thereby can be utilized as a diagnostic means in the vascular system. To ensure that . these microspheres get caught, the size of the micro- sphere must be above 10 u .
- the diameter of the microsphere must be below 1 u . This has been shown by, inter alia, Okamoto et al (Che . Phar . Bull. (1975) 23(7), 1452-1457 who also have shown that the surface structure must be hydrophilic.
- the magnetic albumin microspheres pre- 10 viously mentioned are hydrophobic and cannot therefore circulate, but must be injected arterially towards the target site.
- the present invention provides a magnetically respon sive and biologically degradable nanosphere or nanopar- 20 tide for intravascular administration, which is made up of a matrix in which a magnetic material is enclosed.
- the nanosphere or nanopartiele is characterised in that its average diameter does not exceed 1500 nm, and pre ⁇ ferably is less than 1000 nm, and in that, the matrix 25 is a crystalline carbohydrate.
- Carbohydrate polymers containing alpha(1-4) bonds are especially useful because they can be degraded by the alpha-amylase in the body.
- starch is pre ⁇ ferred, also pullullan, glycogen and dextran may be 30 used. It is also possible to modify the carbohydrate polymer with, for example, hydroxyethyl, hydroxypropyl, acetyl, propionyl, hydroxypropanoyl, various derivatives * of acrylic acid or like substituents.
- carbohydrates which are not polymeric may 35 be used in the context of this invention.
- examples of such carbohydrates are glucose, maltose and lactose.
- compositions may be adsorbed to the carbohydrates after the nanosphere has been produced. This may be y ⁇ '* important in such cases where the pharmaceutical in question is damaged by the treatment in connection with the production of the magnetic nanospheres.
- the matrix is a carbohydrate, it is also possible to modify the matrix by covalently coupling to the carbohydrate e.g. amino groups or carboxylic acid groups, thereby to create an adsorption matrix. High molecular substances of the type proteins may be enclosed within the matrix for later release.
- the invention also comprises a process for the production of magnetic nanospheres having a diameter below 1.5 um. The process is characterised in that a carbohydrate is dissolved in a solvent having a high dielectric constant to form a clear solution.
- the magnetic material is added, whereupon the hydrophilic solution is emulsified in a hydrophobic solvent.
- the resulting emulsion is stabilized by supply ⁇ ing thereto a stabilizing medium, or by transferring the emulsion to such a medium, whereby the carbohydrate is crystallized, while enclosing the magnetic material, to magnetic nanospheres or nanoparticles having an average diameter which does not exceed 1500 nm and pre ⁇ ferably is less than 1000 nm.
- the carbohydrate is dissolved in a concentration which varies from one solvent to another but which nor ⁇ mally lies within the range 5-250% (weight volume) .
- Conceivable such solvents are, inter alia, dimethyl formamide, ethylene glycol, sulpholane, dimethyl sulphoxide, propylene carbonate, water and formamide, or mixtures thereof.
- the magnetic material may consist of magnetic magne ⁇ tite particles (Fe_0.) having a size of 10-20 nm.
- Fe_0. magnetic magne ⁇ tite particles
- One process for the production of such small particles is known, and the particles are commercially available from Ferrofluid Corp. , USA.
- Other useful magnetic ma ⁇ terials include particles or colloids having a substan ⁇ tial content of the aluminium, nickel, cobalt, copper, silver, manganese, or platinum.
- the amount of magnetic particles in the magnetic nanospheres may vary within wide limits. In actual prac- . tice, however, the range is rather narrow, and prefer ⁇ ably use is made of 10-150 parts by weight of magnetic q 5 particles per 100 parts by weight of matrix.
- the mixture of the dissolved carbohydrate and the magnetic material is emulsified in a hydrophobic phase, resulting in the formation of a W/O emulsion.
- the hydrophobic phase em ⁇ ployed may be a vegetable oil, preferably maize oil, 10 or an organic solvent in which one or more emulsifiers have been dissolved.
- useful organic solvents are, inter alia, xylene, toluene, ethyl benzene, diethyl benzene, propyl benzene, ethylene chloride and the like, as well as mixtures thereof.
- the emulsification system 15 which has been found to give the best results, consists of the solvents xylene/CHCl., (4:1) in which the emul- sifiers Pluronic F-68 , and Pluronic L-35 have been dissolved to a concentration of 2.5% (weight volume) of each emulsifier. 20
- a high- pressure homogenizer is used to emulsify the suspension Sonicator or a high- pressure homogenizer is used.
- the resulting emulsion in which the matrix with the magnetic material is sus ⁇ pended in the form of droplets having a maximum size of 2 um, is stabilized by transferring it to a liquid 25 capable of crystallizing the carbohydrate, whereby the magnetic material will be enclosed.
- liquids examples include ethanol, methanol and acetone.
- the preferred liquid is acetone in which Tween 80 ⁇ has been dissolved to a concentration of 0.1% (weight volume).
- the nano- 30 spheres are washed with the said acetone solution * be ⁇ fore they are dried by rotational evaporation or freeze drying. They can also be kept for several months in the acetone solution.
- the pharmacologically active substances can be 35 incorporated with the carrier, on one hand by enclosure, in which case the pharmacologically active substance is mixed with the solution of carbohydrate and the mag- netic material before the solution is emulsified and, on the other hand, by adsorption, in which case the pharmacologically active substance is mixed with the magnetic nanospheres in the aqueous phase.
- dried magnetic nanospheres may be added to a solu ⁇ tion of pharmacologically active.substance, in which case the substance can be coupled covalently to the carbohydrate matrix.
- release is effected by a combination of diffusion and erosion of the matrix, whereas in the case of a covalent coupling of the active substance, release is accomplished by degradation of the matrix. It is also possible to vary the release rate of the pharmacologically active substance by cross-linking the matrix after crystallization. The tighter the matrix is cross-linked, the longer are the release times. Dif ⁇ ferent types of cross-linking agents can be used, de ⁇ pending upon whether or not water is present at the cross-linkage. In aqueous environment, it is possible to use, inter alia, divinyl sulphone, epibromohydrin or BrCN. In the anhydrous phase, it is possible to ac ⁇ tivate with tresyl reagent, followed by cross-linking with a diamine.
- 0.2 g starch were dissolved in 1.0 ml formamide by heating to about 60 C.
- the clear solution was allow- ed to cool to room temperature, whereupon 70 mg magnetite particles (Ferrofluid Corp., Nashua, N.H. , USA) were admixed to the starch solution.
- the solution was trans- ferred to a 100 ml beaker containing 50 ml xylene/CHCl 3 (4:1) in which the emulsifiers Pluronic F- ⁇ and Plu- ronic L-35 ⁇ had been dissolved, both of which had a concentration of 2.5% (weight volume).
- the mixture was emulsified ultrasonically (Ultrasonic 350 G, 350 watt) for 1 in., whereupon the resulting emulsion was trans ⁇ ferred to 400 ml acetone in which the emulsifier Tween ⁇ ⁇ O ⁇ had been dissolved to a concentration of 0.1% (weigh volume) .
- Transfer of the emulsion to the acetone-Tween 80 ⁇ solution was effected by pouring the emulsion in the form of a fine stream into the acetone under stirrin at a rate of about 1000 r/min.
- Example 1 was repeated, but with the difference that instead of 70 mg magnetite particles 100 ul of water-based "Ferrofluid” were admixed to the starch solution (Catalogue No. A-01, 400 gauss from Ferrofluid Corp., Nashua, N.H., USA).
- EXAMPLE 3
- Example 1 was repeated, but with the difference that 140 mg magnetite particles were admixed to the starch solution instead of 70 mg.
- EXAMPLE 4
- Example 1 was repeated, but with the difference that maize oil ( [4 4 : : 1 J1)> ' with the
- Example 1 was repeated, but with the difference that the starch was crystallized in ethanol with the addition of 1 g Tween ⁇ cH per litre of ethanol, instead of acetone.
- Example 1 was repeated, but with the difference that 0.45 g starch was dissolved in 0.1 ml DMSO instead of 0.2 g in formamide.
- Example 1 was repeated, but with the difference that 0.4 g dextran (molecular weight 40,000 from Phar ⁇ macia AB) was dissolved in 1.00 ml water instead of 0.2 g starch in formamide.
- dextran molecular weight 40,000 from Phar ⁇ macia AB
- Example 1 was repeated, but with the difference that 1.5 g lactose was dissolved in 1 ml water, and that the lactose solution was emulsified in oil.
- Example 9 Example 1 was repeated, with the difference that 1.5 g maltose was dissolved in 1 ml water, and that the maltose solution was emulsified in oil.
- EXAMPLE 10 Example 1 was repeated, with the difference that 1.5 g maltose was dissolved in 1 ml water, and that the maltose solution was emulsified in oil.
- Example 1 was repeated, with the difference that 2.5 g glucose were dissolved in 1 ml water, and that the glucose solution was emulsified in oil.
- Examples 1-10 were mixed with H-vincristine, whereupon H-vincristine released by diffusion from the nanospheres was measured in vitro in a 0.1 M Na-phosphate buffer at pH 7.5. After an initially high diffusion from the nanosphere, a relatively uniform leakage was obtained, and after 4 hours 30% of the added amount of H-vin- cristine were still adsorbed to the nanospheres.
- 125 I-labelled ovalbumin had previously been added to the latter solution.
- the dextran-ovalbumin solution was suspended in 25 ml vegetable oil in a 100 ml beaker and cooled to +4°C.
- the mixture was emulsified ultrasonically for 1 min., whereupon the emulsion was poured into 200 ml acetone in which the emulsifier Tween 80 ⁇ had been dis ⁇ solved to a concentration of 0.1% (weight volume). While the emulsion was being carefully poured into the acetone solution, the latter was stirred at a rate of about 1000 r/min.
- the resulting dextran spheres stabilized by crystallization and enclosing ovalbumin and magnetite were washed 4 times more with the said acetone solu ⁇ tion, whereupon they were air-dried.
- Example 1 was repeated, but with the difference that interferon was used instead of ovalbumin.
- Example 1 was repeated, but with the difference that plasmin was used instead of ovalbumin.
- EXAMPLE 15 was repeated, but with the difference that plasmin was used instead of ovalbumin.
- Example 1 The nanospheres produced in Example 1 were used for covalently bonding high-molecular substances of the protein type. 1 ml nanospheres was activated with
- 125I-myoglobin was added and allowed to couple overnight. Unbonded myoglobin was washed off with 1 mM HC1, 0.3 M NaCl and 0.1 M NaHCO.. , pH 9.5, whereupon the activity was determined. 0.7 mg myoglobin had been covalently coupled to the starch matrix.
- Example 1 The magnetic nanospheres obtained in Example 1 were used for in vivo testing on rats.
- the rat was anaesthetised with 5% chloral injected intraperi- toneally, whereupo v. femoralis and the central tail artery were both catheterised cranially.
- the radioac- tively labelled magnetic nanospheres were injected via v. femoralis, and blood samples were taken via the tail artery at predetermined time intervals, whereupon the circulating amount of magnetic nanospheres was deter ⁇ mined.
- the half-life obtained showed that the majority of the number of magnetic nanospheres had such a long half-life in the circulation that they can be concen- trated in an organ of the body to an extent sufficient to attain therapeutical concentration of the transported, pharmaceutically active preparation.
- the rat was killed after a predetermined time, whereupon the amount of magnetic nanospheres in different organs, inter alia the brain, was determined. This experiment was repeated, but this time with the rat's head positioned in a magnetic field of 1 Tesla, and a marked increase of the radioactivity in the brain was observed.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Power Engineering (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
An intravascularly administrable, magnetically responsive nanosphere or nanoparticle made up of a crystalline carbohydrate matrix, preferably starch, enclosing a magnetic material. The nanosphere or nanoparticle is produced by dissolving a carbohydrate together with a magnetic material to form a solution which is emulsified in a hydrophobic solvent from which the carbohydrate is crystallized. The resulting magnetic nanospheres having an average diameter not exceeding 1500 nm are capable of transporting pharmacologically active substances and can be injected intravenously for subsequent concentratioon in a part of the body by means of a magnetic field.
Description
INTRAVASCULARLY ADMINISTRABLE, MAGNETICALLY RESPONSIVE NANOSPHERE OR NANOPARTICLE , A PROCESS FOR THE PRODUCTION THEREOF, AND THE USE THEREOF
The present invention relates to a magnetically responsive and biologically degradable nanosphere or nanopartiele for intravascular administration, to a process for the production thereof, and to the use thereof for the transport and concentration of pharma¬ ceuticals. Background
It has long been desired, in the treatment of dif¬ ferent diseases, to be able specifically to deliver a pharmaceutical to a particular spot in the body, in particular in the treatment of tumours because of the grave systemic secondary effects produced by cytosta- tics. Various chemical methods have been tested in which it was tried to utilize differences in cell structure between tumour cells and healthy cells. However, no such test has been shown to give unequivocal results, above all because the difference between the tumour cells and the healthy cells is so insignificant.
One way of solving this problem is to utilize mag- netic carriers of pharmaceuticals which are injected into the blood-vessel system and transported by the blood to be stopped at the target by means of a magnetic field.
US-PS 4,335,094 (priority June 2, 1977) discloses microspheres containing magnetic material incorporated with a polymer which, in addition, carries biologically active components.
US-PS 4,247,406 contains a detailed description of the use and production of magnetic microspheres made up of a magnetic material which has been enclosed in a polymer consisting of albumin.
One highly important reason for enclosing the mag¬ netic material in a matrix, and for not using only the
magnetic material, is that a matrix makes it possible to transport greater amounts of pharmalogically active substance per icrosphere or microparticle, which is a prior condition of opening up possibilities of pro- viding therapeutical concentrations of the pharmacolo¬ gically active substances at the target site, without increasing the number of microspheres to such an extent that the capillaries are occluded. The requirements placed on the matrix used in such contexts are as fol- lows:
1. The matrix should in itself be chemically inert in biological systems.
2. The matrix should be biologically well-characterised.
3. The matrix should be non-toxic and non-immunogenic. 4. The matrix should be dischargeable from the body via normal routes.
5. The matrix preparation should be readily administrable.
6. The matrix preparation should be able to release a biologically active substance, and the release rate of the active substance should be readily con¬ trollable.
7. The matrix should be usable for enclosing and re¬ leasing substances having different molecular weights.
In addition to polymers of amino acids, such as albumin, carbohydrates are conceivable. Starch and gly- cogen are such carbohydrates made up of glucose units and satisfying the requirements for biocompatibility, primarily because they are the body's own substances, which means that secondary effects in the form of hyper- sensitivity reactions are avoided. The body's own enzyme for degrading starch is alpha-amylase which specifically degrades alpha(1-4) bonds.
The use of starch is disclosed by DE-OS 25 24 278 which describes the preparation and utilization of co- valent cross-linked microspheres of starch having a size so selected that the microspheres will get caught in the capillaries and thereby can be utilized as a
diagnostic means in the vascular system. To ensure that . these microspheres get caught, the size of the micro- sphere must be above 10 u .
To enable a microsphere injected into the vascular 5 system to circulate, the diameter of the microsphere must be below 1 u . This has been shown by, inter alia, Okamoto et al (Che . Phar . Bull. (1975) 23(7), 1452-1457 who also have shown that the surface structure must be hydrophilic. The magnetic albumin microspheres pre- 10 viously mentioned are hydrophobic and cannot therefore circulate, but must be injected arterially towards the target site.
The present specification describes a simple and reproducible process for the production of magnetically 15 responsive crystalline nanospheres or nanoparticles for the concentration of pharmaceuticals. Description of the invention
The present invention provides a magnetically respon sive and biologically degradable nanosphere or nanopar- 20 tide for intravascular administration, which is made up of a matrix in which a magnetic material is enclosed. The nanosphere or nanopartiele is characterised in that its average diameter does not exceed 1500 nm, and pre¬ ferably is less than 1000 nm, and in that, the matrix 25 is a crystalline carbohydrate.
Carbohydrate polymers containing alpha(1-4) bonds are especially useful because they can be degraded by the alpha-amylase in the body. Although starch is pre¬ ferred, also pullullan, glycogen and dextran may be 30 used. It is also possible to modify the carbohydrate polymer with, for example, hydroxyethyl, hydroxypropyl, acetyl, propionyl, hydroxypropanoyl, various derivatives * of acrylic acid or like substituents.
Also carbohydrates which are not polymeric, may 35 be used in the context of this invention. Examples of such carbohydrates are glucose, maltose and lactose.
Pharmaceuticals may be adsorbed to the carbohydrates after the nanosphere has been produced. This may be y ~ '*
important in such cases where the pharmaceutical in question is damaged by the treatment in connection with the production of the magnetic nanospheres. If the matrix is a carbohydrate, it is also possible to modify the matrix by covalently coupling to the carbohydrate e.g. amino groups or carboxylic acid groups, thereby to create an adsorption matrix. High molecular substances of the type proteins may be enclosed within the matrix for later release. The invention also comprises a process for the production of magnetic nanospheres having a diameter below 1.5 um. The process is characterised in that a carbohydrate is dissolved in a solvent having a high dielectric constant to form a clear solution. To this solution, the magnetic material is added, whereupon the hydrophilic solution is emulsified in a hydrophobic solvent. The resulting emulsion is stabilized by supply¬ ing thereto a stabilizing medium, or by transferring the emulsion to such a medium, whereby the carbohydrate is crystallized, while enclosing the magnetic material, to magnetic nanospheres or nanoparticles having an average diameter which does not exceed 1500 nm and pre¬ ferably is less than 1000 nm.
The carbohydrate is dissolved in a concentration which varies from one solvent to another but which nor¬ mally lies within the range 5-250% (weight volume) . Conceivable such solvents are, inter alia, dimethyl formamide, ethylene glycol, sulpholane, dimethyl sulphoxide, propylene carbonate, water and formamide, or mixtures thereof.
The magnetic material may consist of magnetic magne¬ tite particles (Fe_0.) having a size of 10-20 nm. One process for the production of such small particles is known, and the particles are commercially available from Ferrofluid Corp. , USA. Other useful magnetic ma¬ terials include particles or colloids having a substan¬ tial content of the aluminium, nickel, cobalt, copper, silver, manganese, or platinum.
The amount of magnetic particles in the magnetic nanospheres may vary within wide limits. In actual prac- . tice, however, the range is rather narrow, and prefer¬ ably use is made of 10-150 parts by weight of magnetic q 5 particles per 100 parts by weight of matrix. The mixture of the dissolved carbohydrate and the magnetic material is emulsified in a hydrophobic phase, resulting in the formation of a W/O emulsion. The hydrophobic phase em¬ ployed may be a vegetable oil, preferably maize oil, 10 or an organic solvent in which one or more emulsifiers have been dissolved. Among such useful organic solvents are, inter alia, xylene, toluene, ethyl benzene, diethyl benzene, propyl benzene, ethylene chloride and the like, as well as mixtures thereof. The emulsification system 15 which has been found to give the best results, consists of the solvents xylene/CHCl., (4:1) in which the emul- sifiers Pluronic F-68 ,and Pluronic L-35 have been dissolved to a concentration of 2.5% (weight volume) of each emulsifier. 20 To emulsify the suspension Sonicator or a high- pressure homogenizer is used. The resulting emulsion in which the matrix with the magnetic material is sus¬ pended in the form of droplets having a maximum size of 2 um, is stabilized by transferring it to a liquid 25 capable of crystallizing the carbohydrate, whereby the magnetic material will be enclosed. Examples of such liquids are ethanol, methanol and acetone. The preferred liquid is acetone in which Tween 80^has been dissolved to a concentration of 0.1% (weight volume). The nano- 30 spheres are washed with the said acetone solution* be¬ fore they are dried by rotational evaporation or freeze drying. They can also be kept for several months in the acetone solution.
The pharmacologically active substances can be 35 incorporated with the carrier, on one hand by enclosure, in which case the pharmacologically active substance is mixed with the solution of carbohydrate and the mag-
netic material before the solution is emulsified and, on the other hand, by adsorption, in which case the pharmacologically active substance is mixed with the magnetic nanospheres in the aqueous phase. Alternative- ly, dried magnetic nanospheres may be added to a solu¬ tion of pharmacologically active.substance, in which case the substance can be coupled covalently to the carbohydrate matrix.
To enable the pharmacologically active substance to exert its effect, it must be releasable from the carrier material.
When the pharmacologically active substance is enclosed in and/or adsorbed to the crystallized carbo¬ hydrate matrix, release is effected by a combination of diffusion and erosion of the matrix, whereas in the case of a covalent coupling of the active substance, release is accomplished by degradation of the matrix. It is also possible to vary the release rate of the pharmacologically active substance by cross-linking the matrix after crystallization. The tighter the matrix is cross-linked, the longer are the release times. Dif¬ ferent types of cross-linking agents can be used, de¬ pending upon whether or not water is present at the cross-linkage. In aqueous environment, it is possible to use, inter alia, divinyl sulphone, epibromohydrin or BrCN. In the anhydrous phase, it is possible to ac¬ tivate with tresyl reagent, followed by cross-linking with a diamine.
The invention will now be described in more detail with reference to the following Examples which merely serve to illustrate the invention, not to restrict it. EXAMPLE 1
0.2 g starch were dissolved in 1.0 ml formamide by heating to about 60 C. The clear solution was allow- ed to cool to room temperature, whereupon 70 mg magnetite particles (Ferrofluid Corp., Nashua, N.H. , USA) were admixed to the starch solution. The solution was trans-
ferred to a 100 ml beaker containing 50 ml xylene/CHCl3 (4:1) in which the emulsifiers Pluronic F-δδ^and Plu- ronic L-35^had been dissolved, both of which had a concentration of 2.5% (weight volume). The mixture was emulsified ultrasonically (Ultrasonic 350 G, 350 watt) for 1 in., whereupon the resulting emulsion was trans¬ ferred to 400 ml acetone in which the emulsifier Tween ■ δO^had been dissolved to a concentration of 0.1% (weigh volume) . Transfer of the emulsion to the acetone-Tween 80^ solution was effected by pouring the emulsion in the form of a fine stream into the acetone under stirrin at a rate of about 1000 r/min. The crystallized magne¬ tic nanospheres were washed 4 times more with.the said acetone solution, whereafter they were dried under ro- tational evaporation or freeze drying or, alternative¬ ly, were kept in the acetone solution. EXAMPLE 2
Example 1 was repeated, but with the difference that instead of 70 mg magnetite particles 100 ul of water-based "Ferrofluid" were admixed to the starch solution (Catalogue No. A-01, 400 gauss from Ferrofluid Corp., Nashua, N.H., USA). EXAMPLE 3
Example 1 was repeated, but with the difference that 140 mg magnetite particles were admixed to the starch solution instead of 70 mg. EXAMPLE 4
EXAMPLE 5
Example 1 was repeated, but with the difference that the starch was crystallized in ethanol with the addition of 1 g Tween δcH per litre of ethanol, instead of acetone.
EXAMPLE 6
Example 1 was repeated, but with the difference that 0.45 g starch was dissolved in 0.1 ml DMSO instead of 0.2 g in formamide. EXAMPLE 7
Example 1 was repeated, but with the difference that 0.4 g dextran (molecular weight 40,000 from Phar¬ macia AB) was dissolved in 1.00 ml water instead of 0.2 g starch in formamide. EXAMPLE 8
Example 1 was repeated, but with the difference that 1.5 g lactose was dissolved in 1 ml water, and that the lactose solution was emulsified in oil. EXAMPLE 9 Example 1 was repeated, with the difference that 1.5 g maltose was dissolved in 1 ml water, and that the maltose solution was emulsified in oil. EXAMPLE 10
Example 1 was repeated, with the difference that 2.5 g glucose were dissolved in 1 ml water, and that the glucose solution was emulsified in oil. EXAMPLE 11
The magnetic nanospheres obtained in any one of
3 Examples 1-10 were mixed with H-vincristine, whereupon H-vincristine released by diffusion from the nanospheres was measured in vitro in a 0.1 M Na-phosphate buffer at pH 7.5. After an initially high diffusion from the nanosphere, a relatively uniform leakage was obtained, and after 4 hours 30% of the added amount of H-vin- cristine were still adsorbed to the nanospheres. EXAMPLE 12
1 g of a 50% (weight volume) aqueous solution of dextran having a molecular weight of 40,000 was mixed with 70 mg magnetite particles and 100 ul of an ovalbu- min solution containing 100 mg ovalbumin/ml water. 5 ul
125 I-labelled ovalbumin had previously been added to the latter solution.
The dextran-ovalbumin solution was suspended in 25 ml vegetable oil in a 100 ml beaker and cooled to +4°C. The mixture was emulsified ultrasonically for 1 min., whereupon the emulsion was poured into 200 ml acetone in which the emulsifier Tween 80^had been dis¬ solved to a concentration of 0.1% (weight volume). While the emulsion was being carefully poured into the acetone solution, the latter was stirred at a rate of about 1000 r/min. The resulting dextran spheres stabilized by crystallization and enclosing ovalbumin and magnetite were washed 4 times more with the said acetone solu¬ tion, whereupon they were air-dried.
Normally, such an experiment gives a yield of about 250 mg spheres where 60-70% of ovalbumin. added are en- closed in the carbohydrate matrix. EXAMPLE 13
Example 1 was repeated, but with the difference that interferon was used instead of ovalbumin. EXAMPLE 14 Example 1 was repeated, but with the difference that plasmin was used instead of ovalbumin. EXAMPLE 15
The nanospheres produced in Example 1 were used for covalently bonding high-molecular substances of the protein type. 1 ml nanospheres was activated with
20 ul epibromohydrin for 4 hours in 10 ml 0.1 M NaOH.
After washing, 125I-myoglobin was added and allowed to couple overnight. Unbonded myoglobin was washed off with 1 mM HC1, 0.3 M NaCl and 0.1 M NaHCO.. , pH 9.5, whereupon the activity was determined. 0.7 mg myoglobin had been covalently coupled to the starch matrix.
Under the action of alpha-amylase in a concentra¬ tion which was 100 times higher than in normal human serum, about 30% of coupled 125JI-myoglobin had been released from the matrix after 24 hours at room tempe¬ rature and in 0.1 M Na-phosphate buffer, pH 7.5.
The magnetic nanospheres obtained in Example 1 were used for in vivo testing on rats.
To test the half-life in the circulation, the rat was anaesthetised with 5% chloral injected intraperi- toneally, whereupo v. femoralis and the central tail artery were both catheterised cranially. The radioac- tively labelled magnetic nanospheres were injected via v. femoralis, and blood samples were taken via the tail artery at predetermined time intervals, whereupon the circulating amount of magnetic nanospheres was deter¬ mined. The half-life obtained showed that the majority of the number of magnetic nanospheres had such a long half-life in the circulation that they can be concen- trated in an organ of the body to an extent sufficient to attain therapeutical concentration of the transported, pharmaceutically active preparation.
In another experiment, the rat was killed after a predetermined time, whereupon the amount of magnetic nanospheres in different organs, inter alia the brain, was determined. This experiment was repeated, but this time with the rat's head positioned in a magnetic field of 1 Tesla, and a marked increase of the radioactivity in the brain was observed.
Claims
1. A nanosphere or a nanopartiele for intravascular administration, which is magnetically responsive and biologically degradable and which is made up of a matrix in which a magnetic material is enclosed, c h a r a c - t e r i s e d in that it has an average diameter which does not exceed 1500 n , and preferably is less than 1000 nm, and in that the matrix is a crystalline car¬ bohydrate.
2. A nanosphere or a nanopartiele as claimed in claim 1, c h a r a c t e r i s e d in that the magnetic material is present in the form of particles or a col¬ loid.
3. A nanosphere or a nanopartiele as claimed in claim 2, c h a r a c t e r i s e d in that the mag- netic material consists of magnetite particles having an average diameter of 1-1000 nm, preferably 10-20 nm.
4. A nanosphere or a nanopartiele as claimed in one or more of claims 1-3, c h a r a c t e r i s e d in that the crystalline carbohydrate is glucose, maltose or lactose.
5. A nanosphere or a nanopartiele as claimed in one. or more of claims 1-3, c h a r a c t e r i s e d in that the crystalline carbohydrate is a carbohydrate polymer, preferably with alpha(1-4) bonds between the carbohydrates comprised by the polymer.
6. A nanosphere or a nanopartiele as claimed in claim 5, c h a r a c t e r i s e d in that the car¬ bohydrate polymer is starch, glycogen, pullullan or a derivative thereof.
7. A nanosphere or a nanopartiele as claimed in claim 5, c h a r a c t e r i s e d in that the carbo¬ hydrate polymer is dextran or a derivative thereof.
8. A process for the production of a magnetically responsive and degradable nanosphere or nanopartiele for intravascular administration, in which process a magnetic material is enclosed in a matrix, c h a r a c ¬ t e r i s e d in that the matrix is dissolved, in the form of a carbohydrate, in one or more solvents having a high dielectric constant to form.a clear solution, the magnetic material being supplied to said carbohydrat solution, whereupon the hydrophilic solution is emul¬ sified in a hydrophobic solvent, and the resulting emul¬ sion is stabilized by adding a stabilizing medium, or by transferring the emulsion to a stabilizing medium, the carbohydrate crystallizing while enclosing the mag¬ netic material to magnetic nanospheres or nanoparticles having an average diameter which does not exceed 1500 nm and preferably is less than 1000 nm.
9. A process as claimed in claim 8, c h a r a c ¬ t e r i s e d in that the stabilizing medium employed is acetone, ethanol or methanol.
10. Use of the nanosphere or the nanopartiele as claimed in claim 1 for transport and concentration of pharmacologically active substances in biological system preferably animal systems.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU91274/82A AU9127482A (en) | 1981-11-12 | 1982-11-11 | Intravaskulart administrebar, magnetiskt paverkbar nanosfar eller nanopartikel, satt att framstalla denna samt anvandningdarav |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8106723-3811112 | 1981-11-12 | ||
SE8106723 | 1981-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1983001738A1 true WO1983001738A1 (en) | 1983-05-26 |
Family
ID=20345022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1982/000381 WO1983001738A1 (en) | 1981-11-12 | 1982-11-11 | Intravascularly administrable, magnetically responsive nanosphere or manoparticle, a process for the production thereof, and the use thereof |
Country Status (3)
Country | Link |
---|---|
US (1) | US4501726A (en) |
EP (1) | EP0093757A1 (en) |
WO (1) | WO1983001738A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0178769A2 (en) * | 1984-09-11 | 1986-04-23 | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and | Semiconductor implant devices |
US4863715A (en) * | 1984-03-29 | 1989-09-05 | Nycomed As | Method of NMK imaging using a contrast agent comprising particles of a ferromagnetic material |
GB2184015B (en) * | 1985-12-11 | 1990-07-11 | Ceskoslovenska Akademie Ved | Preparation for the diagnostics of the transport function of salpinx and a method for preparation thereof |
EP0447100A1 (en) * | 1990-03-06 | 1991-09-18 | Kelco International Limited | Controlled release formulation |
DE4117782A1 (en) * | 1991-05-28 | 1992-12-03 | Diagnostikforschung Inst | NANOCRYSTALLINE MAGNETIC IRON OXIDE PARTICLES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICAL DIAGNOSTICS AND THERAPY |
DE4325071A1 (en) * | 1993-07-19 | 1995-01-26 | Lancaster Group Ag | Preparation for circulation promotion |
DE4428851A1 (en) * | 1994-08-04 | 1996-02-08 | Diagnostikforschung Inst | Nanoparticles containing iron, their production and application in diagnostics and therapy |
WO1996029998A1 (en) * | 1995-03-28 | 1996-10-03 | Fidia Advanced Biopolymers S.R.L. | Nanospheres comprising a biocompatible polysaccharide |
US5618514A (en) * | 1983-12-21 | 1997-04-08 | Nycomed Imaging As | Diagnostic and contrast agent |
EP0782851A1 (en) * | 1993-03-02 | 1997-07-09 | Biovector Therapeutics Sa | Synthetic particulate vectors and method for preparing same |
AU2001294068B2 (en) * | 2000-10-16 | 2005-12-22 | Consejo Superior De Investigaciones Cientificas | Nanoparticles |
DE112006004066T5 (en) | 2006-10-13 | 2009-08-20 | Aleksandr Mettalinovich Tishin | A magnetic carrier and medical preparation for controllably delivering and releasing drugs, methods of preparation thereof, and methods of treatment using the same |
WO2009127045A1 (en) * | 2008-04-16 | 2009-10-22 | Stemcell Technologies Inc. | Magnetic particles |
US20140054162A1 (en) * | 2012-08-24 | 2014-02-27 | The University Of Akron | Magnetic macroinitiators and magnetically induced chain reactions |
EP2323708A4 (en) * | 2008-08-07 | 2015-11-18 | Exogenesis Corp | Drug delivery system and method of munufacturing thereof |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4713249A (en) * | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
SE463651B (en) * | 1983-12-21 | 1991-01-07 | Nycomed As | DIAGNOSTIC AND CONTRACTOR |
US6203777B1 (en) * | 1983-12-21 | 2001-03-20 | Nycomed Imaging As | Method of contrast enhanced magnetic resonance imaging using carbohydrate particles |
US5720939A (en) * | 1985-08-15 | 1998-02-24 | Nycomed Imaging As | Method of contrast enhanced magnetic resonance imaging using magnetically responsive-particles |
DE3440288C2 (en) * | 1984-11-05 | 1987-03-12 | Gergely, Gerhard, Dr.-Ing., Wien | Pharmaceutical preparation containing ibuprofen and process for its preparation |
PT81498B (en) * | 1984-11-23 | 1987-12-30 | Schering Ag | METHOD FOR PREPARING COMPOSITIONS FOR DIAGNOSTICS CONTAINING MAGNETIC PARTICLES |
US4795698A (en) * | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
US5160745A (en) * | 1986-05-16 | 1992-11-03 | The University Of Kentucky Research Foundation | Biodegradable microspheres as a carrier for macromolecules |
US4951675A (en) * | 1986-07-03 | 1990-08-28 | Advanced Magnetics, Incorporated | Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging |
US5219554A (en) | 1986-07-03 | 1993-06-15 | Advanced Magnetics, Inc. | Hydrated biodegradable superparamagnetic metal oxides |
US5248492A (en) * | 1986-07-03 | 1993-09-28 | Advanced Magnetics, Inc. | Low molecular weight carbohydrates as additives to stabilize metal oxide compositions |
US5160726A (en) * | 1990-02-15 | 1992-11-03 | Advanced Magnetics Inc. | Filter sterilization for production of colloidal, superparamagnetic MR contrast agents |
US5102652A (en) * | 1986-07-03 | 1992-04-07 | Advanced Magnetics Inc. | Low molecular weight carbohydrates as additives to stabilize metal oxide compositions |
US4770183A (en) * | 1986-07-03 | 1988-09-13 | Advanced Magnetics Incorporated | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents |
US5336506A (en) * | 1986-07-03 | 1994-08-09 | Advanced Magnetics Inc. | Targeting of therapeutic agents using polysaccharides |
US5141739A (en) * | 1986-07-03 | 1992-08-25 | Advanced Magnetics, Inc. | Delivery of x-ray contrast agents using receptor mediated endocytosis |
US5554386A (en) * | 1986-07-03 | 1996-09-10 | Advanced Magnetics, Inc. | Delivery of therapeutic agents to receptors using polysaccharides |
DE3723310A1 (en) * | 1987-07-15 | 1989-01-26 | John Urquhart | PHARMACEUTICAL PREPARATION AND METHOD FOR THE PRODUCTION THEREOF |
US4835033A (en) * | 1988-03-01 | 1989-05-30 | General Dynamics Land Systems, Inc. | Armor plate having triangular holes |
CA1334936C (en) * | 1988-04-01 | 1995-03-28 | Walter Whitson-Fischman | Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration |
US5162037A (en) * | 1988-04-01 | 1992-11-10 | Whitson Laboratories, Inc. | Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration |
US5129877A (en) * | 1988-04-29 | 1992-07-14 | University Of Georgia Research Foundation, Inc. | Receptor-mediated delivery system |
US5213800A (en) * | 1989-02-09 | 1993-05-25 | Diamond Scientific Company | Chlorhexidine disinfectant granules |
US5125888A (en) * | 1990-01-10 | 1992-06-30 | University Of Virginia Alumni Patents Foundation | Magnetic stereotactic system for treatment delivery |
EP0707856A3 (en) | 1990-02-15 | 1999-01-20 | Advanced Magnetics Incorporated | Filter sterilization for production of colloidal, superparamagnetic MR contrast agents |
US5358702A (en) * | 1990-04-10 | 1994-10-25 | Unger Evan C | Methoxylated gel particle contrast media for improved diagnostic imaging |
US5441739A (en) * | 1990-06-22 | 1995-08-15 | The Regents Of The University Of California | Reduced and controlled surface binding of biologically active molecules |
US5219577A (en) * | 1990-06-22 | 1993-06-15 | The Regents Of The University Of California | Biologically active composition having a nanocrystalline core |
US5460830A (en) * | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Biochemically active agents for chemical catalysis and cell receptor activation |
US5460831A (en) * | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Targeted transfection nanoparticles |
US5462751A (en) * | 1990-06-22 | 1995-10-31 | The Regeants Of The University Of California | Biological and pharmaceutical agents having a nanomeric biodegradable core |
US5334394A (en) * | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
US5306508A (en) * | 1990-06-22 | 1994-04-26 | The Regents Of The University Of California | Red blood cell surrogate |
KR930006431B1 (en) * | 1990-10-11 | 1993-07-16 | 재단법인 한국화학연구소 | Microcapsulation of drugs |
GB9106686D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
GB9200388D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
AU6165394A (en) * | 1993-01-29 | 1994-08-15 | Magnetic Delivered Therapeutics, Inc. | Magnetically responsive composition for carrying biologically active substances and methods of production and use |
US6200547B1 (en) | 1994-01-26 | 2001-03-13 | Ferx Incorporated | Magnetically responsive compositions for carrying biologically active substances and methods of production and use |
US6482436B1 (en) | 1993-01-29 | 2002-11-19 | Ferx Incorporated | Magnetically responsive composition |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
CA2174244A1 (en) * | 1993-11-01 | 1995-05-11 | Nir Kossovsky | Biochemically active agents for chemical catalysis and cell receptor activation |
US6007845A (en) * | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5466440A (en) * | 1994-12-30 | 1995-11-14 | Eastman Kodak Company | Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays |
US5628981A (en) * | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
US5503723A (en) * | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US6423296B1 (en) * | 1996-01-10 | 2002-07-23 | Amersham Health As | Constrast media |
GB9600427D0 (en) * | 1996-01-10 | 1996-03-13 | Nycomed Imaging As | Contrast media |
US5855868A (en) * | 1996-04-01 | 1999-01-05 | Nycomed Imaging As | Method of T1 -weighted resonance imaging of RES organs |
DE19631563A1 (en) * | 1996-07-26 | 1998-02-26 | Frank Dr Ing Lux | Pure or functionalised electroconductive polymer material |
US6135118A (en) * | 1997-05-12 | 2000-10-24 | Dailey; James P. | Treatment with magnetic fluids |
GB9815271D0 (en) | 1998-07-14 | 1998-09-09 | Cambridge Display Tech Ltd | Particles and devices comprising particles |
US6177088B1 (en) | 1999-01-07 | 2001-01-23 | Fayette Environmental Services, Inc. | Surface-functionalized, probe-containing nanospheres |
US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
ES2188343B1 (en) * | 2000-11-14 | 2004-11-16 | Universidad De Zaragoza.O.T.R.I. | PRODUCTION OF MONODISPERSE MAGNETIC NANOPARTICLES WITH A REGULABLE SIZE USING AN ORGANIC POLYMER. |
US20020082679A1 (en) * | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US20030033007A1 (en) * | 2000-12-22 | 2003-02-13 | Avantec Vascular Corporation | Methods and devices for delivery of therapeutic capable agents with variable release profile |
US20030050692A1 (en) * | 2000-12-22 | 2003-03-13 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
US6471980B2 (en) | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
US7083642B2 (en) * | 2000-12-22 | 2006-08-01 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
US6939375B2 (en) | 2000-12-22 | 2005-09-06 | Avantac Vascular Corporation | Apparatus and methods for controlled substance delivery from implanted prostheses |
US7077859B2 (en) * | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US20050203612A1 (en) * | 2000-12-22 | 2005-09-15 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
EP1990040A1 (en) * | 2001-07-10 | 2008-11-12 | North Carolina State University | Nanoparticle delivery vehicle |
ES2278952T3 (en) * | 2001-07-26 | 2007-08-16 | Avantec Vascular Corporation | DEVICES FOR MANAGING THERAPEUTIC AGENTS WITH VARIABLE LIBERATION PROFILE. |
US20040210289A1 (en) * | 2002-03-04 | 2004-10-21 | Xingwu Wang | Novel nanomagnetic particles |
BR0307544A (en) | 2002-02-01 | 2004-12-07 | Ariad Gene Therapeutics Inc | Phosphorus-containing compounds, components and composition as well as their use by treatment methods |
US7249604B1 (en) | 2002-05-10 | 2007-07-31 | Vasmo, Inc. | Medical devices for occlusion of blood flow |
US7670623B2 (en) * | 2002-05-31 | 2010-03-02 | Materials Modification, Inc. | Hemostatic composition |
US7560160B2 (en) * | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
US20040133099A1 (en) | 2002-12-18 | 2004-07-08 | Dyer R. Kent | Otologic nanotechnology |
DE10331439B3 (en) * | 2003-07-10 | 2005-02-03 | Micromod Partikeltechnologie Gmbh | Magnetic nanoparticles with improved magnetic properties |
US7007972B1 (en) | 2003-03-10 | 2006-03-07 | Materials Modification, Inc. | Method and airbag inflation apparatus employing magnetic fluid |
US20050240100A1 (en) * | 2003-04-08 | 2005-10-27 | Xingwu Wang | MRI imageable medical device |
US20040254419A1 (en) * | 2003-04-08 | 2004-12-16 | Xingwu Wang | Therapeutic assembly |
US20050261763A1 (en) * | 2003-04-08 | 2005-11-24 | Xingwu Wang | Medical device |
US20050079132A1 (en) * | 2003-04-08 | 2005-04-14 | Xingwu Wang | Medical device with low magnetic susceptibility |
US20050278020A1 (en) * | 2003-04-08 | 2005-12-15 | Xingwu Wang | Medical device |
US20050025797A1 (en) * | 2003-04-08 | 2005-02-03 | Xingwu Wang | Medical device with low magnetic susceptibility |
US20050155779A1 (en) * | 2003-04-08 | 2005-07-21 | Xingwu Wang | Coated substrate assembly |
US20050244337A1 (en) * | 2003-04-08 | 2005-11-03 | Xingwu Wang | Medical device with a marker |
US6982501B1 (en) | 2003-05-19 | 2006-01-03 | Materials Modification, Inc. | Magnetic fluid power generator device and method for generating power |
US8651113B2 (en) * | 2003-06-18 | 2014-02-18 | Swr&D Inc. | Magnetically responsive nanoparticle therapeutic constructs and methods of making and using |
US7723311B2 (en) * | 2003-06-18 | 2010-05-25 | Nanobiomagnetics, Inc. | Delivery of bioactive substances to target cells |
US7344491B1 (en) | 2003-11-26 | 2008-03-18 | Nanobiomagnetics, Inc. | Method and apparatus for improving hearing |
DK2279729T3 (en) * | 2003-07-17 | 2016-11-28 | Banner Life Sciences Llc | Control release preparations |
US7200956B1 (en) | 2003-07-23 | 2007-04-10 | Materials Modification, Inc. | Magnetic fluid cushioning device for a footwear or shoe |
CA2538395A1 (en) * | 2003-09-12 | 2005-03-24 | Bankruptcy Estate Of Ferx, Inc. | Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents |
US7448389B1 (en) | 2003-10-10 | 2008-11-11 | Materials Modification, Inc. | Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid |
WO2005051229A2 (en) * | 2003-11-24 | 2005-06-09 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
US20070027532A1 (en) * | 2003-12-22 | 2007-02-01 | Xingwu Wang | Medical device |
CN100333715C (en) * | 2004-01-02 | 2007-08-29 | 孙永海 | Magnetic medicinal microball for directional breaking nerve back root and its preparing method |
US9028829B2 (en) * | 2004-02-20 | 2015-05-12 | The Children's Hospital Of Philadelphia | Uniform field magnetization and targeting of therapeutic formulations |
US8562505B2 (en) * | 2004-02-20 | 2013-10-22 | The Children's Hospital Of Philadelphia | Uniform field magnetization and targeting of therapeutic formulations |
US7846201B2 (en) * | 2004-02-20 | 2010-12-07 | The Children's Hospital Of Philadelphia | Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex |
CN1976681A (en) * | 2004-03-26 | 2007-06-06 | 弗尔克斯破产财产公司 | Magnetically targetable mitomycin C compositions and methods of their use |
EP1730516A1 (en) * | 2004-03-30 | 2006-12-13 | Pfizer Products Incorporated | Method and device for evaluation of pharmaceutical compositions |
US8012457B2 (en) * | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
US20070150051A1 (en) * | 2005-01-10 | 2007-06-28 | Duke Fiduciary, Llc | Vascular implants and methods of fabricating the same |
US8287583B2 (en) | 2005-01-10 | 2012-10-16 | Taheri Laduca Llc | Apparatus and method for deploying an implantable device within the body |
US20070264199A1 (en) * | 2005-09-26 | 2007-11-15 | Labhasetwar Vinod D | Magnetic nanoparticle composition and methods for using the same |
US7931778B2 (en) * | 2005-11-04 | 2011-04-26 | Cargill, Incorporated | Lecithin-starches compositions, preparation thereof and paper products having oil and grease resistance, and/or release properties |
EP2023813A4 (en) * | 2006-05-15 | 2013-03-13 | Dmitri B Kirpotin | Magnetic microparticles comprising organic substances |
WO2008065502A1 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein |
EP2114303A4 (en) | 2007-02-09 | 2012-08-08 | Taheri Laduca Llc | Vascular implants and methods of fabricating the same |
WO2008125940A2 (en) * | 2007-04-17 | 2008-10-23 | Pfizer Products Inc. | Nanoparticles comprising non-crystalline drug |
WO2008135852A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles and casein |
US8703204B2 (en) * | 2007-05-03 | 2014-04-22 | Bend Research, Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer |
WO2008135828A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
US9545384B2 (en) | 2007-06-04 | 2017-01-17 | Bend Research, Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate |
EP2162120B1 (en) * | 2007-06-04 | 2016-05-04 | Bend Research, Inc | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
WO2009010842A2 (en) * | 2007-07-13 | 2009-01-22 | Pfizer Products Inc. | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
US9233078B2 (en) * | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
WO2009073215A1 (en) * | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
WO2009081287A2 (en) * | 2007-12-21 | 2009-07-02 | University Of Guelph | Polysaccharide nanoparticles |
CN102186766B (en) | 2008-08-06 | 2015-07-08 | 生命科技公司 | Water-dispersable nanoparticles |
EP2387787B1 (en) | 2008-12-19 | 2018-09-12 | Ferronova Pty Ltd | Magnetic nanoparticles |
US8685458B2 (en) | 2009-03-05 | 2014-04-01 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
US9060938B2 (en) | 2011-05-10 | 2015-06-23 | Bend Research, Inc. | Pharmaceutical compositions of active agents and cationic dextran polymer derivatives |
DE102011112898A1 (en) * | 2011-09-08 | 2013-03-14 | Charité - Universitätsmedizin Berlin | Nanoparticulate phosphate adsorbent based on maghemite or maghemite / magnetite, its preparation and uses |
WO2013166487A1 (en) | 2012-05-04 | 2013-11-07 | Yale University | Highly penetrative nanocarriers for treatment of cns disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2524278A1 (en) * | 1974-06-06 | 1975-12-18 | Pharmacia Ab | DIAGNOSTIC MEANS, AIDS FOR PRODUCTION AND DIAGNOSIS METHODS |
WO1978000005A1 (en) * | 1977-06-02 | 1978-12-07 | K H Mosbach | Magnetic polymer particles |
DE2828941A1 (en) * | 1978-06-30 | 1980-01-10 | Robert Thomas Gordon | CANCER TREATMENT AGENTS |
US4247406A (en) * | 1979-04-23 | 1981-01-27 | Widder Kenneth J | Intravascularly-administrable, magnetically-localizable biodegradable carrier |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4357259A (en) * | 1977-08-01 | 1982-11-02 | Northwestern University | Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres |
US4345588A (en) * | 1979-04-23 | 1982-08-24 | Northwestern University | Method of delivering a therapeutic agent to a target capillary bed |
DE2925009A1 (en) * | 1979-06-21 | 1981-01-08 | Basf Ag | PREPARATION FOR SUBSTANCES, METHOD FOR THE PRODUCTION AND USE THEREOF |
US4331654A (en) * | 1980-06-13 | 1982-05-25 | Eli Lilly And Company | Magnetically-localizable, biodegradable lipid microspheres |
DE19744052C1 (en) * | 1997-10-06 | 1998-10-22 | Lucas Ind Plc | Electronically controlled valve for vehicle braking force booster |
-
1982
- 1982-11-11 WO PCT/SE1982/000381 patent/WO1983001738A1/en unknown
- 1982-11-11 US US06/522,159 patent/US4501726A/en not_active Expired - Fee Related
- 1982-11-11 EP EP82903367A patent/EP0093757A1/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2524278A1 (en) * | 1974-06-06 | 1975-12-18 | Pharmacia Ab | DIAGNOSTIC MEANS, AIDS FOR PRODUCTION AND DIAGNOSIS METHODS |
WO1978000005A1 (en) * | 1977-06-02 | 1978-12-07 | K H Mosbach | Magnetic polymer particles |
DE2828941A1 (en) * | 1978-06-30 | 1980-01-10 | Robert Thomas Gordon | CANCER TREATMENT AGENTS |
US4247406A (en) * | 1979-04-23 | 1981-01-27 | Widder Kenneth J | Intravascularly-administrable, magnetically-localizable biodegradable carrier |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6544496B1 (en) | 1983-12-21 | 2003-04-08 | Amersham Health As | Diagnostic and contrast agent |
US5817291A (en) * | 1983-12-21 | 1998-10-06 | Nycomed Imaging As | Method of ultrasonic imaging comprising administering biocompatible spheres or particles |
US5670135A (en) * | 1983-12-21 | 1997-09-23 | Nycomed Imaging As | Ultrasonic contrast agent comprising carbohydrate particles |
US5618514A (en) * | 1983-12-21 | 1997-04-08 | Nycomed Imaging As | Diagnostic and contrast agent |
US4863715A (en) * | 1984-03-29 | 1989-09-05 | Nycomed As | Method of NMK imaging using a contrast agent comprising particles of a ferromagnetic material |
EP0178769A2 (en) * | 1984-09-11 | 1986-04-23 | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and | Semiconductor implant devices |
EP0178769A3 (en) * | 1984-09-11 | 1986-04-30 | The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And | Silicon implant devices |
US4793825A (en) * | 1984-09-11 | 1988-12-27 | The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom And Northern Ireland | Active silicon implant devices |
GB2184015B (en) * | 1985-12-11 | 1990-07-11 | Ceskoslovenska Akademie Ved | Preparation for the diagnostics of the transport function of salpinx and a method for preparation thereof |
EP0447100A1 (en) * | 1990-03-06 | 1991-09-18 | Kelco International Limited | Controlled release formulation |
DE4117782A1 (en) * | 1991-05-28 | 1992-12-03 | Diagnostikforschung Inst | NANOCRYSTALLINE MAGNETIC IRON OXIDE PARTICLES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICAL DIAGNOSTICS AND THERAPY |
US5427767A (en) * | 1991-05-28 | 1995-06-27 | Institut Fur Diagnostikforschung Gmbh An Der Freien Universitat Berlin | Nanocrystalline magnetic iron oxide particles-method for preparation and use in medical diagnostics and therapy |
EP0782851A1 (en) * | 1993-03-02 | 1997-07-09 | Biovector Therapeutics Sa | Synthetic particulate vectors and method for preparing same |
DE4325071A1 (en) * | 1993-07-19 | 1995-01-26 | Lancaster Group Ag | Preparation for circulation promotion |
DE4428851A1 (en) * | 1994-08-04 | 1996-02-08 | Diagnostikforschung Inst | Nanoparticles containing iron, their production and application in diagnostics and therapy |
DE4428851C2 (en) * | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Nanoparticles containing iron, their production and application in diagnostics and therapy |
WO1996029998A1 (en) * | 1995-03-28 | 1996-10-03 | Fidia Advanced Biopolymers S.R.L. | Nanospheres comprising a biocompatible polysaccharide |
AU2001294068B2 (en) * | 2000-10-16 | 2005-12-22 | Consejo Superior De Investigaciones Cientificas | Nanoparticles |
DE112006004066T5 (en) | 2006-10-13 | 2009-08-20 | Aleksandr Mettalinovich Tishin | A magnetic carrier and medical preparation for controllably delivering and releasing drugs, methods of preparation thereof, and methods of treatment using the same |
WO2009127045A1 (en) * | 2008-04-16 | 2009-10-22 | Stemcell Technologies Inc. | Magnetic particles |
CN102067250A (en) * | 2008-04-16 | 2011-05-18 | 干细胞技术公司 | Magnetic particles |
EP2277181A4 (en) * | 2008-04-16 | 2016-03-09 | Stemcell Technologies Inc | Magnetic particles |
US9701935B2 (en) | 2008-04-16 | 2017-07-11 | Stemcell Technologies Inc. | Magnetic particles |
EP2323708A4 (en) * | 2008-08-07 | 2015-11-18 | Exogenesis Corp | Drug delivery system and method of munufacturing thereof |
US20140054162A1 (en) * | 2012-08-24 | 2014-02-27 | The University Of Akron | Magnetic macroinitiators and magnetically induced chain reactions |
US9545611B2 (en) * | 2012-08-24 | 2017-01-17 | The University Of Akron | Magnetic macroinitiators and magnetically induced chain reactions |
Also Published As
Publication number | Publication date |
---|---|
US4501726A (en) | 1985-02-26 |
EP0093757A1 (en) | 1983-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4501726A (en) | Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof | |
EP0785776B1 (en) | Preparation of protein microspheres, films and coatings | |
US4871716A (en) | Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof | |
Péan et al. | Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres? | |
US4345588A (en) | Method of delivering a therapeutic agent to a target capillary bed | |
US5238714A (en) | Efficient microcapsule preparation and method of use | |
US6602524B2 (en) | Microspheres for use in the treatment of cancer | |
Cui et al. | Multi-stimuli responsive smart chitosan-based microcapsules for targeted drug delivery and triggered drug release | |
US4671954A (en) | Microspheres for incorporation of therapeutic substances and methods of preparation thereof | |
JP3296817B2 (en) | Oral distribution system suitable for fine particles | |
US20090258076A1 (en) | Water-soluble magnetic or metal oxide nanoparticles coated with ligands, preparation method and usage thereof | |
JP5147699B2 (en) | Protein nanoparticles and uses thereof | |
JP4350165B2 (en) | Cross-linked fine particles and their use as therapeutic vehicles | |
EP0042249A2 (en) | Magnetically-localizable, biodegradable lipid microspheres | |
IE47305B1 (en) | Intravascularly-administrable,magentically-localizable biodegradable carrier and process for its preparation | |
Gurung et al. | An overview on microspheres | |
Ghassabian et al. | Dexamethasone-loaded magnetic albumin microspheres: Preparation and in vitro release | |
CA2263765C (en) | Methods for the production of protein particles useful for delivery of pharmacological agents | |
JP2006241321A (en) | Method for producing chitosan nanoparticle, chitosan particle, coating composition, sustained release preparation, and injection | |
WO1989003674A1 (en) | Microspheres, way of producing said microspheres and the use thereof | |
JPS6163613A (en) | Sustained release preparation | |
WO1998017257A1 (en) | Porous microcapsules and their use as therapeutic and diagnostic vehicles | |
JP2727326B2 (en) | Temperature sensitive microspheres | |
EP1683517A1 (en) | Methods for the production of protein particles useful for delivery of pharmacological agents | |
Deshmukh et al. | Microspheres: As new drug delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): AU DK JP US |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB LU NL SE |